

May 15-16, 2023 | Boston Marriott Copley Place | Boston, MA | pharmamanworld.com

MAY 14, 2023

# **AGENDA**

6:00 - 7:00 pm



### **MAY 15, 2023**

7:00 - 7:45 am

**Registration and Breakfast** 

Sponsored By:



7:45 - 7:50 am Opening Remarks and Important Announcements

7:50 - 8:00 am Chair's Welcome Address





Charles L. Cooney
Robert T. Haslam Professor of Chemical
Engineering, Emeritus, and Faculty
Director, Emeritus Deshpande Center for
Technological Innovation
MIT

8:00 - 8:35 am

### Operational Excellence, Innovation & Teamwork as Enablers for Reimagining Medicine

As Novartis begins its journey to become a focused innovative medicines company, the Operations organization is evolving to make this ambition into a reality. A few years ago, we undertook a systematic approach of improving and optimizing our manufacturing capabilities. We brought in best practices, methodologies and tools to streamline processes, eliminate waste, reduce costs, improve quality and efficiency. We recognize that we have embarked on a continuous journey and we are happy to share how far we have come on:

- Operational Excellence: Embedding operational excellence to improve productivity and deliver high-quality medicines
- Innovation: Expanding platform capabilities in RNA, Cell & Gene therapies, Radioligand therapies as well as in Large &
- **Teamwork:** Unleashing the power of our people to combine a wealth of experience and expertise, leveraging the diversity of our teams





Steffen Lang President of Operations Novartis

8:35 - 9:10 am

### Our Journey in Next Generation Manufacturing: What We Can Achieve Together

- Where our organizations are heading as a community of pharmaceutical manufacturers
- Our current and future capabilities by geography, people, and technology
- Practical leadership approaches that empower us to tackle challenges and set ambitious goals for the future
- Next generation platforms that will change how we work and succeed
- Examples from Pfizer that illustrate these pursuits in action





Jim Cafone SVP Global Supply Chain

## **ROOM 1 CHAIR**





Charles L. Cooney Robert T. Haslam Professor of Chemical Engineering, Emeritus, and Faculty Director, Emeritus Deshpande Center for Technological Innovation

# **ROOM 2 CHAIR**





Teresa Gorecki Practice Lead **Compliance Architects** 

# **ROOM 3 CHAIR**

# RESILIENCE




Tori Arens VP GM & Site Head Resilience, Inc.

9:15 - 9:50 am

## Managing Innovation and Variability in a Growth Environment

- How the pandemic impacted the structure and responsiveness of our global networks
- Responding to new geographic fluctuation of demand by disease states and patient delivery
- The challenges and opportunities posed by new product innovation and managing lifecycles

BREAKOUT





**Andy Wirths** SVP Supply Americas **AstraZeneca** 

9:15 - 9:50 am

# ROOM 2

## The Uncommon, Common Sense of Organizational Change Management

- The unfortunate truth behind organizational change management failures.
- What every executive leader should know regarding organizational change management.
- The role of executive leaders in organizational change strategy and implementation.
- Practical examples of successful organizational change.





Laquisha E. Crawford
Executive Director, Development
and Commercial Biologics Quality
Gilead Sciences

9:15 - 9:50 am

## BREAKOUT ROOM 3 CELL & GENE THERAPY

## **Evolving Our Supply Chain: Enabling Competitive Advantage through Strategic E2E Integration**

- What is an Integrated Platform Supply Chain and how does it enhance Customer Centricity?
- What are the Core Foundational elements and business outcomes of a strategic integration?
- How is Talent development accelerated in an Integrated Supply Chain?
- How the creation of segmented partnerships and operational constructs have become an agility driver





Luis Roman
VP Global Platform LeaderSmall Molecules
Johnson & Johnson

9:55 - 11:35 am

## **Pre-Arranged One-to-One Meetings**

10:00 am - 10:20 am: Meeting Slot 1/Networking 10:25 am - 10:45 am: Meeting Slot 2/Networking 10:50 am - 11:10 am: Meeting Slot 3/Networking 11:15 am - 11:35 am: Meeting Slot 4/Networking

11:40 am - 12:15 pm



# Why Your Digital Strategy May Be Incomplete: How Legacy Models Prevent End-To-End Digital Manufacturing

- Why pharma organizations must diversify their digitization strategy, looking beyond legacy models that prevent complete, end-to-end digital manufacturing
- How a light, configurable MES can remove paper from production entirely and enable any-sized pharma company to fully utilize their MES across all lines and sites
- How a modern MES can digitally connect different data sources to close offline data gaps, improve data integrity and visibility, and unlock critical business intelligence





Marty Smyth SVP, Go-To-Market Strategy MasterControl 11:40 am - 12:15 pm



### Al in Action: Leveraging Al to Maximize Quality and Efficiency in Drug Manufacturing

- Advanced technologies like Al are the keys to making your manufacturing data more useful
- Leveraging AI in two different areas:
  - From clinical supply to scale up to full production manufacturing: How can you use your historical data and Al to help you transform and improve your tech transfer and production processes?
  - o Yield optimization use case: How AI can help you reduce waste and optimize batch production





Andy Alasso
Chief Product and
Customer Success Officer
Aizon

11:40 am - 12:15 pm

# The Iterative Approach to a Digital Cell and Gene Therapy Process – an Overview & Best Practice

- Specific challenges in the digitization of CGT manufacturing
- Digital enablement of traceability in patient-specific processes
- A best practice approach to implementing electronic batch records for CGT
- An overview of digital data management for CGT processes







Judith Koliwer, PhD
Principal Consultant, Cell & Gene Therapy
Körber Pharma Software

12:20 - 12:55 am

# BREAKOUT ROOM 1 STRATEGIC MANUFACTURING

## Fireside Chat: The Emerging Role of the CDMO in Commercialization of Advanced Therapeutics

- With rapidly evolving science driving new therapeutic modalities, what is the role of a CDMO?
- The challenges of process development with accelerated approvals
- Building a manufacturing network to address tomorrow's needs
- What are the implications of the IRA legislation on the future of biotherapeutic manufacturing?

RESILIENCE



Spencer Fisk
Chief Technology Officer
Resilience Inc.

12:20 - 12:55 pm

# BREAKOUT ROOM 2

## Rethinking, Reinvesting, and Reinvigorating Our Quality and Compliance Processes

- Highlighting the Ultragenyx "Responsible Quality Mindset" culture
- Discuss the role of senior leadership commitment to implementing impactful change and creating a supportive, speak-up culture
- Driving ownership and employee engagement. Putting "Quality is everyone's responsibility" into practice.
- Establishing strong quality performance management. What are the KPIs and metrics that matter?
- Fostering a learning environment. How the focus on employee development drives quality performance.
- Encouraging continuous improvement
- Highlighting some of our success stories. What can other organizations on their own journeys learn from our experience?





Kathy Azuara SVP Global Quality Ultragenyx 12:20 - 12:55 pm

BREAKOUT ROOM 3 SUPPLY CHAIN Digitization and Visibility: The Future of Supply Chain Operations - a Small Parcel Distribution

Case Study TBA





Tim Elliott
Executive Director, North
America Supply Chain Operations
Merck





Rich Kilmer CEO CargoSense

12:55 - 1:55 pm

**EXECUTIVE LUNCH SEATING** 

Sponsored By:



Germfree

12:55 - 1:55 pm

#### THEMED LUNCH DISCUSSIONS

Themed lunches are roundtable discussions on specific industry issues and challenges during lunch hour. Each roundtable will be led by a sponsor or delegate who is an expert in the field. Limited seating is available, so please sign up for your preferred topic through the event app. Choose from:

Using Effective Risk Communication to Facilitate Regulatory Approvals





Sarah Miksinski Executive Director AstraZeneca Last Mile to the Patient in Cell & Gene Therapy





Christopher Temple VP, Operations Athersys Building an Early Clinical-Stage Global Supply Chain to Support Autologous Cell-Based Product in Rare Indications

# **AUREGEN**



José Manuel Otero Chief Technical Officer Auregen

Establishment of a Platform Technology: Process Characterization, Technology Transfer and Manufacturing

Considerations for Success



Resource Forecasting and Agile Capacity Management Strategies





Julie Go
Executive Director,
Technical Operations Strategy
Seagen

Lean/Six-Sigma Approaches in Biopharma Manufacturing





Carl Finamore
Executive Director Gene
Therapy Manufacturing
Ultragenyx

Digitization in Clinical
Manufacturing: Opportunities and
Lessons Learned

moderna



**Brendan Walker** Sr. Director, Digital Site Lead **Moderna**  Developing and Deploying a Quality Culture Excellence Program

ultragenyX



Ndidi Rickert Associate Director, Quality Culture Excellence Ultragenyx

1:55 - 2:30 pm

# BREAKOUT ROOM 1 STRATEGIC

### The Vertex Story: Serial Innovation in Manufacturing

- Sharing Vertex's track record for serial innovation in manufacturing to create transformative medicines for people with serious diseases and high unmet medical needs
- Highlighting Vertex's success with small molecule continuous manufacturing in Cystic Fibrosis
- Transforming manufacturing in cell and genetic therapies for Sickle Cell Disease, Beta Thalassemia, and Type 1 Diabetes





Morrey Atkinson
SVP & Head, Commercial
Manufacturing and Supply Chain
Vertex Pharmaceuticals

1:55 - 2:30 pm

# BREAKOUT ROOM 2 QUALITY

### **BEAST – Bioassay Standardization and Harmonization**

- Offering an overview of one of the more complex assays used to support therapeutic product development
- Discussing the practical and often complex elements of bioassays, ranging from critical reagents (e.g.-cell line, ligands, serum) to reference standard and plate control
- Demonstrating that the sustainability of these elements is vital to establishing and maintaining bioassays over the lifecycle of a therapeutic product
- Offering best practices to ensure testing is done at the right place and the right time
- Optimizing lab efficiency to provide timely accurate results
- Walking through our approach for standardization and harmonization of bioassays from initial commercialization through the end
  of the product lifecycle



**Babita Parekh**VP Analytical Sciences and Global
Bioassay Steward **Eli Lilly** 

1:55 - 2:30 pm

## **Bespoke Dosing and Manufacturing for Pediatric Patients**

BREAKOUT ROOM 3 SUPPLY CHAIN





Rick Panicucci SVP CMC BridgeBio

2:35 pm - 3:10 pm

WORKSHOP

# Build vs Buy vs Blend: Comparing Challenges and Opportunities for Early-Phase Biopharmaceutical Manufacturing Options

- Exploring and comparing various options available to the biopharma industry for the manufacturing of clinical batches
- Looking at: Internal manufacturing, outsourced manufacturing, and hybrid models
- What are the current challenges and opportunities for these options? Discussing various considerations including economic and time





Ravi Samavedam Chief Innovation Officer Azzur Group



Chris Mansur EVP of Corporate Development Azzur Group

2:35 pm - 3:10 pm

**WORKSHOP** 

# Your "Future-Proofed" Platform Is Holding You Back: Look to the Future with Connected Life Sciencesn

- Is the platform approach the "be-all and end-all" of software solutions?
- Facing the challenge of no "one-size-fits-all" solution for every organization
- How certain approaches to quality can disrupt other parts of the business and upheave proven working systems in order to continue platform building
- Avoiding gaps in critical applications causing inefficiencies, as well as limiting the ability to make data-driven decisions
- Introducing you to a better way in which you don't have to stop using the solutions and technology you've invested in
- Showing you how to enhance your infrastructure and pillar systems with minimal disruption
- Discussing why a connected life sciences approach is the future of quality





Joe Goodman
VP Solutions Engineering & Customer
Engagement
Sparta Systems, A Honeywell Company

2:35 pm - 3:10 pm

### **Technical Operations Strategies for Transformative Medicines**

- Current trends and manufacturing strategies for next-generation medicines
- Best in class practices for facility planning, build, operational readiness and startup
- New innovative technologies on the horizon

Panelists:





Kara Price VP, Site Lead Pfizer





**Charlie Harper** *VP* **Project Farma** 





Leading the Microbiome Revolution\*



**David Ege**Chief Technology Officer, EVP Process
Development, Quality & Supply **Seres Therapeutic** 

**Moderator:** 





**Adam Pfeiffer** VP **Project Farma** 

3:15 - 4:25 pm

#### **Pre-Arranged One-to-One Meetings**

 $3:15~\rm pm-3:35~\rm pm:$  Meeting Slot 5 / Networking 3:40 pm  $-4:00~\rm pm:$  Meeting Slot 6 / Networking 4:05 pm  $-4:25~\rm pm:$  Meeting Slot 7 / Networking

4:30 - 5:05 pm

### **Quality and Compliance from the Regulators' Perspective**

- What are regulators looking for when they engage with QA/QC executives and other senior leaders? How can industry facilitate
  these interactions?
- Thinking about your processes and facilities from the point of view of the inspector: What are you taking for granted based on familiarity or habit or tradition that would not apply to a fresh pair of eyes?
- Highlighting best practices to make ongoing documentation a powerful quality and compliance tool for the future
- Using compliance as a starting point: What does exceeding expectations look like, and how should pharmaceutical manufacturers stay ahead of that moving target in perpetuity?





Peter Marks
Director – Center for Biologics
Evaluation and Research (CBER)
FDA

5:05 - 5:50 pm

### Panel: 'Next' Generation Manufacturing: What Did We Learn and Where Are We Going?

- Discuss how today's pipeline and technologies are reshaping biomanufacturing
- Looking at the technologies that enable next generation manufacturing processes
- Review case studies and strategies for rapid manufacturing scale up for leading products
- Focus on the necessity of investing in people and robust strategies to support the workforce and culture
- Show opportunities that allow for successful navigation in the future of manufacturing, including leveraging legacy and culture
  as drivers of change





Chris Horan Chief Technical Operations Officer Artiva Biotherapeutics





Tim Moore EVP, Chief Technical Officer Allogene





Craig Kennedy SVP Global Supply Chain Moderna

**RESILIENCE** 



Pat Yang Vice Chairman & Co-Founder Resilience, Inc.

5:50 - 6:00 pm

### **Chair's Closing Remarks**





Charles L. Cooney
Robert T. Haslam Professor of Chemical
Engineering, Emeritus, and Faculty
Director, Emeritus Deshpande Center for
Technological Innovation
MIT

6:00 - 7:00 pm

# Drinks Reception YTTT

6:30 pm



**MAY 16, 2023** 

7:30 - 8:25 am

**Registration and Breakfast** 

Sponsored By:



7:45 - 8:20 am



### SmartFactory Rx® 2.0: Lessons Learned to Digitize our Pharma Future

- · Optimizing productivity and quality for manufacturing resilience and sustainability
- The flavors of Pharma 4.0
- The journey of defining the high value problems and opportunities
- Initial gains and deployment of real-time technology for continuous improvement
- Practical use cases of SmartFactory Rx: End to ... well the journey never ends





**Amy Doucette**Head of Business Operations **APG Pharma** 



Rick Johnston PhD
Head of Manufacturing
Data Science
APG Pharma

#### **Chair's Welcome Remarks**





Charles L. Cooney
Robert T. Haslam Professor of Chemical
Engineering, Emeritus, and Faculty
Director, Emeritus Deshpande Center for
Technological Innovation
MIT

8:35 - 9:10 am

# Leading Through Transformations and Integrations – The Evolution of Global Product Development and Supply

Karin Shanahan, EVP, Global Product Development and Supply at Bristol Myers Squibb joins us to discuss how she is leading one of the world's largest manufacturing operations through rapid transformation, while integrating cutting-edge technology into BMS. Among the highlights, Karin will discuss:

- How GPS delivers value to the enterprise through the Product Development and R&D interface.
- The integration of Cell Therapy into GPS and how the company is working to improve predictability long-term.
- Establishing a competitive advantage for BMS from within GPS an operational model built to last. Karin will also include successful examples of GPS's evolution to support the New Product Pipeline, most notably the recently

Bristol Myers Squibb

approved Opdualag.



Karin Shanahan EVP, Global Product Development and Supply Bristol-Myers Squibb

9:10 - 9:45 am

# Fireside Chat: The New Normal and Beyond: How to Design the Fit for Purpose Technical Operations Organization of the Future

- The Pharma/BioPharma ecosystem is rapidly evolving with new technology and innovative business models
- People and how we organize and empower them is at the core of competitive advantage
- We must consider geography, education and culture in training and retaining our most important asset
- With an increase in new modalities such as cell therapy, there is a new generation of Tech Ops professionals to train and nurture
- We need to examine how automation and Al might change workforce activities, productivity and workflow
- The Message: The Tech Ops organization of the future is being built today, your success depends on how we train and organize our people





Carlo de Notaristefani Former Lead, Manufacturing & Supply Chain Advisor Operation Warp Speed

# **ROOM 1 CHAIR**





Charles L. Cooney
Robert T. Haslam
Professor of Chemical
Engineering, Emeritus,
and Faculty Director,
Emeritus Deshpande
Center for Technological
Innovation
MIT

# **ROOM 2 CHAIR**





Teresa Gorecki Practice Lead Compliance Architects LLC

# **ROOM 3 CHAIR**

# RESILIENCE



Tori Arens VP GM & Site Head Resilience, Inc.

9:50 - 10:25 am

# A Look into the Future: How Pharmaceutical Manufacturing Is Transforming to Bring Hope to Patients

# BREAKOUT ROOM 1 STRATEGIC

- Highlighting what industry will need to do differently to achieve an ambitious future where all patients can receive lifesaving medicines safely, swiftly, reliably, and affordably
- Providing a glimpse of how the world will evolve as molecular complexity increases in the future for small molecules, blurring the boundaries between small and large molecules
- Exploring the role that new technologies will play in achieving that transformation





Jennifer Baxter
VP, Small Molecule Science and
Technology
Merck

9:50 - 10:25 am

# BREAKOUT ROOM 2

Integrating OE and QMS- An (In Process) Journey to Quality as a Competitive Advantage

 How setting up formal structures and investing in key people capabilities engages all levels of employees and allows a Quality Management System to push beyond a sole focus on processes and procedures

راأا Bristol Myers Squibb



Kaoru Nishino
Executive Director, Global
Quality Management Systems
Bristol-Myers Squibb

9:50 - 10:25 am

# ROOM 3 SUPPLY CHAIN

Supply Chain Constraints of High Value Raw Materials in mRNA Product Manufacturing

- Discussing the challenge of supplying small, medium and large patient populations: What makes sense now, and what does the future hold?
- Implementing emerging technologies to facilitate modern demand driven supply chain processes
- Leveraging Data and Analytics to build a smarter supply chain to better serve patients
- Improving communication and visibility across the supply chain to drive efficient outcomes
- Assessing the potential of Machine Learning, IoT, Blockchain & Artificial Intelligence to drive our supply chain goals





Murali Muralidhara
Chief Technical & Manufacturing Officer
RVAC Medicines, Boston, US

10:25 - 11:15 am

# **Pre-Arranged One-to-One Meetings**

10:30 am - 10:50 am: Meeting Slot 8 / Networking 10:05 am - 11:15 am: Meeting Slot 9 / Networking

10:40 - 11:15 am

### **Industry Focus Group**

An industry focus group is an informal moderated conversations among peers that occur during networking time outside the regularly scheduled conference agenda. There is no sign up. Delegates and speakers are welcome to opt in. The focus group will take place in the Exhibition Hall in a well-marked area. All participants will be provided with wireless headphones to ensure everything said can be heard over the background noise of the Exhibition Hall.

#### INDUSTRY FOCUS GROUP — TALENT

## The Evolution of Manufacturing: Exploring the Digital Vision for the Future of our Industry





Richard D. Braatz
Edwin R. Gilliland Professor
of Chemical Engineering
MIT

11:20 - 11:55 pm

# Transforming a Global Development & Product Supply Network for Delivering a Multi-Modal Portfolio – It's More than Flexible Facilities

- Re-designing your organization to leverage capabilities across modalities In agile ways
- Designing technology platforms as you design products
- Laying the foundation for change during a pandemic builds flexibility and resilience in employees, setting the course for new
  ways of working and breaking down silos
- Strengthening a culture of inclusion and driving diversity in leadership ranks





Jens Vogel SVP & Global Head of Biotech Bayer Pharmaceuticals

12:00 - 12:35 pm

# WORKSHOP BREAKOUT ROOM 1

## Can Al Deliver a 'Real' Advantage for Life Sciences Manufacturing?

- Exceed customer expectations, earn stakeholder trust, and positively impact the future of health
- How an increasing focus on digital transformation is creating opportunities for manufacturers to meet the challenges of disruption and a competitive marketplace
- Are you making the most of the tremendous volume of data being collected?
- Leveraging your organization's data foundation to provide actionable insights that enable improved decision-making and lead to positive outcomes across the manufacturing process
- Learn how data analytics and Al can help deliver insights that:
  - o Improve product yield
  - o Increase manufacturing efficiencies
  - o Streamline quality control
  - o Reduce maintenance and equipment costs
  - o Improve sustainability
  - o Plug into existing platforms.

Through consistent results, fuel your company's growth strategy and build a competitive advantage in delivering essential drugs and health care supplies to patients and their care givers when and where they are needed.



Kim Forte Principal, SCNO Deloitte Consulting LLP



Iknam Gill Sr. Manager, SCNO Deloitte Consulting LLP

Deloitte.



Aishwarya Mantha Product Management Lead Deloitte Consulting LLP

12:00 - 12:35 pm

# WORKSHOP BREAKOUT ROOM 2

### **Global Talent Trends in Pharma and Biotech Technical Operations: A Perfect Storm**

- The great reckoning single-asset company valuation recalibrations reverse top talent trend and lead to unprecedented layoffs in the industry
- The generational gap continues to progress leading only becomes more challenging
- Leaders in the healthcare industry indicate the greatest drop in leadership confidence across industries





Michael Kamarck Board of Directors Passage Bio





Pascal Bécotte
Managing Director
Russell Reynolds Associates

12:00 - 12:35 pm

## WORKSHOP BREAKOUT ROOM 3

Panel: Beyond Capabilities & Capacity: What Traits Should Biopharma Companies Look for When Partnering with CDMOs

- Best traits to look for when partnering with a CDMO, besides just capabilities and capacity
- Best practices for discerning which CDMO's are best for biopharma companies to partner with
- Key steps for helping biopharma companies navigate complex sales processes with CDMOs





Amy Lovasco New Products Integration Lead, External Supply Pfizer





Omar Kassim
Director of CDMO
Relationship Management,
PharmSci R&D
Takeda Pharmaceuticals

**Moderator:** 





Brad Wynja VP of Business Development INCOG BioPharma Services

12:35 - 1:35 pm

**EXECUTIVE LUNCH SEATING** 

Sponsored By:



12:35 - 1:35 pm



# INTERACTIVE THINK TANK LUNCHES

During the Day Two Executive Lunch there will be three different 'Interactive Think Tank' topics set up in the Exhibition Hall.

These are informal and unmoderated networking opportunities for like-minded attendees to get together in small groups to brainstorm and discuss issues of common interest. Icebreaking questions and topics of possible conversation will be provided but are by no means mandatory.

TOPIC 1

Digital Transformation Tactics & Strategies

TOPIC 2

Talent Attraction, Training, & Retention CMO/CDMO Challenges

1:35 - 2:10 pm

### BREAKOUT ROOM 1 STRATEGIC MANUFACTURING

## **Designing the Next-Generation Advanced Therapeutics Manufacturing Process**





Richard D. Braatz
Edwin R. Gilliland Professor
of Chemical Engineering
MIT

1:35 - 2:10 pm

# BREAKOUT ROOM 2

### Quality Leadership before Quality Metrics and Quality Management Maturity

- CDER, FDA, has low confidence in quality management of the pharmaceutical industry due to drug shortages, which they state has manufacturing quality issues as the main cause.
- Industry is accountable for ensuring cGMP compliance and quality of products. However, companies can't continually improve their
  manufacturing processes to prevent drug shortages in a matter of weeks or months as changes require national health authorities
  approval prior to implementation. This usually takes years for full global approval of each change. So how do we solve this paradox
  of need for change, yet change takes years? By working together in new ways.
- From industry side it takes quality leadership, which is being discussed in this presentation. You'll hear about engaging the C-Suite and employees at all levels, what an effective quality system looks like, effective communication, how to apply Deming and Juran's teaching and more.





Anders Vinther
SVP Pharmaceutical
Development & Manufacturing
Kronos Bio

2:15 - 3:00 pm

# Panel: How will the Way People, Processes, and Technologies Interact Change in the Next Ten Years?

- Discussing some of the forces and factors that are changing the way we operate
- Debating how these influences will continue to evolve, and how they will shape our organizations
- Technological progress is a given, but will there also be fundamental changes to our people and our processes in the next decade, or should we expect incremental modifications rather than a sea change?
- Thinking about Risk Management: How should we brace ourselves for the unexpected in a global business environment whose only constant factor is change?





Joanne Beck
Chief Technology
Officer
Aerium Therapeutics





**Tim Moore** EVP, Chief Technical Officer **Allogene** 





Craig Beasley
Chief Technology Officer
BlueRock Therapeutics

3:00 - 3:05 pm

### **Chair's Closing Remarks**





Charles L. Cooney
Robert T. Haslam Professor of Chemical
Engineering, Emeritus, and Faculty
Director, Emeritus Deshpande Center for
Technological Innovation
MIT